Human CILP-1 N-Terminal Fragment Antibody Summary
Accession # NP_003604
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Detection of Human CILP‑1 N-Terminal Fragment by Western Blot. Western blot shows lysates of human cartilage tissue. PVDF membrane was probed with 1 µg/mL of Goat Anti-Human CILP-1 N-Terminal Fragment Antigen Affinity-purified Polyclonal Antibody (Catalog # AF5504) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF019). A specific band was detected for CILP-1 at approximately 100-110 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 8.
Detection of Human CILP‑1 by Simple WesternTM. Simple Western lane view shows lysates of human cartilage tissue, loaded at 0.2 mg/mL. A specific band was detected for CILP-1 at approximately 133 kDa (as indicated) using 10 µg/mL of Goat Anti-Human CILP-1 N-Terminal Fragment Antigen Affinity-purified Polyclonal Antibody (Catalog # AF5504) followed by 1:50 dilution of HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF109). This experiment was conducted under reducing conditions and using the 66-440 kDa separation system.
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
The CILP-1 (cartilage intermediate-layer protein 1) gene product is a 132 kDa (predicted) monomeric glycoprotein that is found in both hyaline and fibrocartilage. It is a precursor for two secreted, proteolytically generated products, a 90 kDa N-terminal CILP-1, and a 62 kDa C-terminal NTPPHase-homolog. The N-terminus is suggested to serve as both a matrix structural protein, and an IGF-I/TGF-beta 1 suppressor sequestration molecule. Human CILP-1 spans aa 22‑720 of the CILP-1 precursor. It contains one TSP-1 domain (aa 149‑201), a C2‑type Ig-like region (aa 309‑395) and six potential N-glycosylation sites. Over aa 1‑720 of the CILP-1 precursor, human CILP-1 shares 89% aa identity with mouse CILP‑1, and 42% aa identity with human CILP-2.
Citation for Human CILP-1 N-Terminal Fragment Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
Cartilage intermediate layer protein 1 (CILP1): A novel mediator of cardiac extracellular matrix remodelling
Authors: FA van Nieuwe, C Munts, RC Op't Veld, A González, J Díez, S Heymans, B Schroen, M van Bilsen
Sci Rep, 2017;7(1):16042.
Sample Types: Tissue Homogenates
Applications: Western Blot
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human CILP-1 N-Terminal Fragment Antibody
There are currently no reviews for this product. Be the first to review Human CILP-1 N-Terminal Fragment Antibody and earn rewards!
Have you used Human CILP-1 N-Terminal Fragment Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image